Showing results (91-100 of 148) with videos related to

Sort By:
Pageof 15
Cancer Research|December 15, 1990
Pharmacokinetics and metabolism of cyclopentenyl cytosine in nonhuman primatesS M Blaney, F M Balis, L Hegedus, et al.
The American Journal of Pediatric Hematology/Oncology|January 1, 1989
Chronopharmacokinetics of oral methotrexate and 6-mercaptopurine: is there diurnal variation in the disposition of antileukemic therapy?F M Balis, S L Jeffries, B Lange, et al.
Cancer Research|September 15, 1995
A phase I trial of amifostine (WR-2721) and melphalan in children with refractory cancerP C Adamson, F M Balis, J E Belasco, et al.
Anti-Cancer Drugs|April 1, 1993
A phase I trial of trimetrexate (NSC352122) on a daily x 5 schedule in patients with refractory adult leukemiaG Rodriguez, T D Brown, F M Balis, et al.
Cancer Research|June 1, 1993
Pharmacokinetics of piroxantrone in a phase I trial of piroxantrone and granulocyte-colony stimulating factorS L Berg, D M Savarese, F M Balis, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 1, 1992
Phase I/II trial and pharmacokinetics of intrathecal diaziquone in refractory meningeal malignanciesS L Berg, F M Balis, S Zimm, et al.
The Journal of Pharmacology and Experimental Therapeutics|August 17, 2000
Pharmacokinetics and metabolism of the methotrexate metabolite 2, 4-diamino-N(10)-methylpteroic acidB C Widemann, E Sung, L Anderson, et al.
The New England Journal of Medicine|October 6, 1988
Effect of continuous intravenous infusion of zidovudine (AZT) in children with symptomatic HIV infectionP A Pizzo, J Eddy, J Falloon, et al.
Clinical Pharmacology and Therapeutics|April 1, 1987
The effect of methotrexate on the bioavailability of oral 6-mercaptopurineF M Balis, J S Holcenberg, S Zimm, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 18, 1997
Phase I trial and pharmacokinetic study of all-trans-retinoic acid administered on an intermittent schedule in combination with interferon-alpha2a in pediatric patients with refractory cancerP C Adamson, G Reaman, J Z Finklestein, et al.
Pageof 15